Moreover, the LEADER study demonstrated, for the first time for treatment with a GLP1 receptor agonist, a reduction in cardiovascular and total mortality in patients with type 2 diabetes mellitus.32 Although weight reduction was not a primary endpoint in the LEADER trial, treatment with Liraglutide resulted in a weight loss of 2.3 kg over placebo. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.